Cargando…

Use of Biological Treatments in Elderly Patients with Skin Psoriasis in the Real World

Biological drugs have prompted a revolution in the treatment of patients with psoriasis because of their favourable efficacy/risk profile. The aims of our study are to determine whether there is any difference in the pattern of use of biological treatments for older (65+ years) and younger patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Osuna, Cristina Galache, García, Sebastián Reyes, Martín, Jimena Carrero, Jiménez, Virginia García, López, Francisco Vázquez, Santos-Juanes, Jorge
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705752/ https://www.ncbi.nlm.nih.gov/pubmed/34947880 http://dx.doi.org/10.3390/life11121348

Ejemplares similares

Ustekinumab Drug Survival in Patients with Psoriasis: A retrospective Study of Real Clinical Practice
por: Galache Osuna, Cristina, et al.
Publicado: (2020)

Acne Inversa-like Lesions Induced by a Low Dose of Sorafenib
por: Aubán-Pariente, Javier, et al.
Publicado: (2021)

Biologics for psoriasis patients under 18 years of age: Real-world evidence from the Chinese psoriasis real world evidence research group
por: Zheng, Yu-Xin, et al.
Publicado: (2022)

Durability of Near-Complete Skin Clearance in Patients with Psoriasis Using Systemic Biologic Therapies: Real-World Evidence from the CorEvitas Psoriasis Registry
por: McLean, Robert R., et al.
Publicado: (2023)

Skin Clearance is Associated with Reduced Treatment Failure in Patients with Psoriasis: Real-World Evidence from the CorEvitas Psoriasis Registry
por: McLean, Robert R., et al.
Publicado: (2023)

Anti‐interleukin‐23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real‐world practice
por: Ruggiero, A., et al.
Publicado: (2021)

Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence
por: Lin, Pei-Tzu, et al.
Publicado: (2018)

Looking beyond the Skin: Pathophysiology of Cardiovascular Comorbidity in Psoriasis and the Protective Role of Biologics
por: Andújar, Isabel, et al.
Publicado: (2022)

Rate of biological invasions is lower in coastal marine protected areas
por: Ardura, A., et al.
Publicado: (2016)

A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate‐to‐severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO‐BIO‐REAL)
por: Seneschal, J., et al.
Publicado: (2020)

Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan
por: Chen, Yu-Chen, et al.
Publicado: (2020)

Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study
por: Pirro, Federico, et al.
Publicado: (2021)

Dose Adjustment of Biologic Treatments for Moderate-to-Severe Plaque Psoriasis in the Real World: A Systematic Review
por: Gambardella, Alessio, et al.
Publicado: (2021)

Nevi, biologics for psoriasis and the risk for skin cancer: A real concern? (Case presentation and short review)
por: Bujoreanu, Florin Ciprian, et al.
Publicado: (2021)

Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort
por: VAN MUIJEN, Marloes. E., et al.
Publicado: (2022)

The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios
por: Rajagopalan, Murlidhar, et al.
Publicado: (2021)

Real World Studies of Psoriasis and Mental Illness in Newfoundland and Labrador
por: Badaiki, Winifred, et al.
Publicado: (2022)

Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement
por: Ger, Tzong-Yun, et al.
Publicado: (2019)

The CANOVA Study Real-World Evidence of Biologic Treatments in Moderate-Severe Psoriasis in Italy: A Gender Perspective
por: Colombo, Delia, et al.
Publicado: (2022)

Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data
por: Ruggiero, Angelo, et al.
Publicado: (2023)

Real‐world dose adjustments of biologic treatments in psoriasis and their economic impact: a Swedish national population study
por: Egeberg, Alexander, et al.
Publicado: (2022)

Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: Real-World Data from a Care Center in Romania
por: Lupea-Chilom, Doriana-Sorina, et al.
Publicado: (2023)

Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database
por: Calapai, Fabrizio, et al.
Publicado: (2023)

Safety Assessment of Conventional and Biological Systemic Therapy in Older Adults with Psoriasis, a Real-world Multicentre Cohort Study
por: TER HAAR, Elke L. M., et al.
Publicado: (2022)

Biologic Therapy for Moderate to Severe Psoriasis. Real-World Follow-up of Patients Who Initiated Biologic Therapy at Least 10 Years Ago
por: Elberdín, Laida, et al.
Publicado: (2022)

Cell biology and the “real world”
por: Blackstone, Craig, et al.
Publicado: (2016)

Psoriasis Therapy and Skin Cancer: A Review
por: Butrón-Bris, Beatriz, et al.
Publicado: (2021)

Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months
por: Blauvelt, Andrew, et al.
Publicado: (2021)

Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice
por: Hung, Yi-Teng, et al.
Publicado: (2021)

Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World Setting
por: Strober, Bruce, et al.
Publicado: (2022)

Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan(®) Databases
por: Leonardi, Craig, et al.
Publicado: (2022)

Real‐world, long‐term treatment patterns of commonly used biologics in Canadian patients with moderate‐to‐severe chronic plaque psoriasis
por: Gooderham, Melinda J., et al.
Publicado: (2021)

Real-World Insight on Apremilast Therapy in Patients with Plaque Psoriasis: Indian Experience
por: De, Abhishek, et al.
Publicado: (2020)

Real-world Efficacy and Safety of Apremilast Monotherapy in the Management of Moderate-to-severe Psoriasis
por: Shah, Bela J., et al.
Publicado: (2020)

Does the Vehicle Matter? Real-World Evidence on Adherence to Topical Treatment in Psoriasis
por: Teixeira, Ana, et al.
Publicado: (2021)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Real-world use of ustekinumab therapeutic drug monitoring in moderate to severe psoriasis
por: Elberdín, Laida, et al.
Publicado: (2022)

Artificial Intelligence–Based Psoriasis Severity Assessment: Real-world Study and Application
por: Huang, Kai, et al.
Publicado: (2023)

Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data
por: Toribio-García, Irene, et al.
Publicado: (2023)

Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)
por: Mahil, S.K., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kqvc4eutbg4500kcgn48er7t32